Predictive value of HIV-1 viral load on risk for opportunistic infection

被引:0
作者
Swindells, S [1 ]
Evans, S
Zackin, R
Goldman, M
Haubrich, R
Filler, SG
Balfour, HH
机构
[1] Univ Nebraska, Med Ctr, Omaha, NE 68198 USA
[2] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
[3] Indiana Univ, Sch Med, Indianapolis, IN 46204 USA
[4] Univ Calif San Diego, La Jolla, CA 92093 USA
[5] Univ Calif Los Angeles, Harbor Res & Educ Inst, Torrance, CA USA
[6] Univ Minnesota, Minneapolis, MN USA
关键词
opportunistic infection; viral load; candidiasis;
D O I
10.1097/01.QAI.0000017998.56638.8E
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: The relationship between HIV-1 viral load and the risk for opportunistic infection (OI) was examined in Adult AIDS Clinical Trial Group (AACTG) 722, a virology substudy of AACTG 323: a phase 4 randomized Study designed to examine the use of chronic suppressive versus episodic fluconazole therapy. Methods: The primary analysis used a case-control sampling scheme with two controls per "case" (subjects that developed an OI) matched by gender, age, and time on study. Forty-five cases and matched controls were identified and used in the analysis. Results: Study 722 accrued 518 subjects between 5/97 and 11/99. Forty-five subjects developed serious OIs or refractory candidiasis. Median baseline CD4 count was 24 cell/mm(3) for cases and 46 for controls ( p = .003). Median viral load (VL) was 5.02 log(10) copies/mL for cases and 4.08 for controls (p = .002). Multivariate analysis found four independent variables associated with time to OI: baseline VL and CD4 (RR = 2.2 per log increment and 6.0 per 50-cell increment, respectively), a one log increase in VL at any time (RR = 15), and history of an OI (RR = 5.2). Conclusions: VL and changes in VL were independently associated with risk of development of OIs in a prospective study and should be considered by clinicians when assessing patients for risk of OI.
引用
收藏
页码:154 / 158
页数:5
相关论文
共 30 条
  • [1] [Anonymous], 1992, MMWR Recomm Rep, V41, P1
  • [2] Colgan R, 2001, AM FAM PHYSICIAN, V64, P999
  • [3] Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count -: A randomized, double-blind, placebo-controlled trial
    Currier, JS
    Williams, PL
    Koletar, SL
    Cohn, SE
    Murphy, RL
    Heald, AE
    Hafner, R
    Bassily, EL
    Lederman, HM
    Knirsch, C
    Benson, CA
    Valdez, H
    Aberg, JA
    McCutchan, JA
    [J]. ANNALS OF INTERNAL MEDICINE, 2000, 133 (07) : 493 - 503
  • [4] HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
    Deeks, SG
    Hecht, FM
    Swanson, M
    Elbeik, T
    Loftus, R
    Cohen, PT
    Grant, RM
    [J]. AIDS, 1999, 13 (06) : F35 - F43
  • [5] Determinants of virological response to antiretroviral therapy: Implications for long-term strategies
    Deeks, SG
    [J]. CLINICAL INFECTIOUS DISEASES, 2000, 30 : S177 - S184
  • [6] Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine - AIDS clinical trials group protocol 320
    Demeter, LM
    Hughes, MD
    Coombs, RW
    Jackson, JB
    Grimes, JM
    Bosch, RJ
    Fiscus, SA
    Spector, SA
    Squires, KE
    Fischl, MA
    Hammer, SM
    [J]. ANNALS OF INTERNAL MEDICINE, 2001, 135 (11) : 954 - 964
  • [7] Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy.
    El-Sadr, WM
    Burman, WJ
    Grant, LB
    Matts, JP
    Hafner, R
    Crane, L
    Zeh, D
    Gallagher, B
    Mannheimer, SB
    Martinez, A
    Gordin, F
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (15) : 1085 - 1092
  • [8] Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy
    Furrer, H
    Egger, M
    Opravil, M
    Bernasconi, E
    Hirschel, B
    Battegay, M
    Telenti, A
    Vernazza, PL
    Rickenbach, M
    Flepp, M
    Malinverni, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (17) : 1301 - 1306
  • [9] Both serum HIV type 1 RNA levels and CD4+ lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4+ cells per cubic millimeter
    Kim, S
    Hughes, MD
    Hammer, SM
    Jackson, JB
    DeGruttola, V
    Katzenstein, DA
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (07) : 645 - 653
  • [10] Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study
    Ledergerber, B
    Egger, M
    Opravil, M
    Telenti, A
    Hirschel, B
    Battegay, M
    Vernazza, P
    Sudre, P
    Flepp, M
    Furrer, H
    Francioli, P
    Weber, R
    [J]. LANCET, 1999, 353 (9156) : 863 - 868